Literature DB >> 16865646

Hereditary medullary thyroid cancer in Slovenia--genotype-phenotype correlations.

Damijan Bergant1, Marko Hocevar, Nikola Besic, Damjan Glavac, Branka Korosec, Simon Caserman.   

Abstract

BACKGROUND: Medullary thyroid cancer (MTC) is a rare endocrine tumor that may be sporadic or inherited in settings of MEN2A, MEN2B and FMTC. Germline point mutations in the RET proto-oncogene are responsible for tumor occurrence, inheritance and great clinical variability. The aim of this study was to correlate the genotype and phenotype of patients with hereditary MTC (age at diagnosis, sex, TNM classification and clinical features). PATIENTS: Between 1997 and 2003 genetic testing was performed in 69 out of 98 patients with "sporadic" MTC. Carriage of mutation was found in 14 (20.2%) patients (index patients) and in 16 out of 31 (51.6%) of their relatives. One patient with MEN2B and codon 918 mutation was excluded from further analysis.
METHODS: Genomic DNA was isolated from peripheral blood leukocytes. Exons 10, 11, 13, 14, 15 and 16 of the RET proto-oncogene were amplified in polymerase chain reactions. Point mutations of the RET gene were detected with single-strand conformation analysis and DNA sequencing. Detected mutations were confirmed with restriction enzyme analysis.
RESULTS: Codon 634 mutations were detected in 15 patients (50%; aged 18-76 years; 6 families), codon 618 in nine patients (30%; aged 12-65 years; 4 families) and codon 790 in five patients (16.6%; aged 16-74 years; 3 families). The median age at diagnosis was 31 +/- 17.3, 33 +/- 15.9 and 36 +/- 23.8 years for patients with codon 618, 634 and 790 mutations. Selected by sex, females with codon mutations 618 and 634 versus 790 had median age at diagnosis of 34.5 +/- 15.6 years and 43.5 +/- 22.9 years, whereas the inverse result was observed in males (26.5 +/- 18.0 versus 16 years). The male/female ratio was 1:2 for patients with codon 618 and 634 mutations and 1:4 for patients with codon 790 mutations. Some of the data suggested correlation between specific genotypes, tumor size, stage of MTC and age at diagnosis. Pheochromocytoma (12 out of 15 patients) and primary hyperparathyroidism (6 out of 15 patients) were diagnosed solely in patients with codon 634 mutations. One patient with FMTC and Hirschprung disease was found in a family with codon 618 mutations.
CONCLUSION: Correlation between tumor size, stage of MTC at diagnosis in view of patient's age, and specific genotype were indicated in our limited series and were more evident in female patients with codon 790 mutations. Later onset and a probably less aggressive course of MTC in these patients than in patients with other mutations should be considered in planning prophylactic thyroid surgery. MEN2A syndrome was related solely to codon 634 mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865646     DOI: 10.1007/s00508-006-0636-8

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  28 in total

Review 1.  The surgical treatment of medullary thyroid carcinoma.

Authors:  D B Evans; J B Fleming; J E Lee; G Cote; R F Gagel
Journal:  Semin Surg Oncol       Date:  1999 Jan-Feb

2.  Family screening in medullary thyroid carcinoma presenting without a family history.

Authors:  B A Ponder; N Finer; R Coffey; C L Harmer; M Maisey; M G Ormerod; M E Pembrey; M A Ponder; P Rosswick; S Shalet
Journal:  Q J Med       Date:  1988-04

3.  Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.

Authors:  Linwah Yip; Gilbert J Cote; Suzanne E Shapiro; Gregory D Ayers; Cynthia E Herzog; Rena V Sellin; Steven I Sherman; Robert F Gagel; Jeffrey E Lee; Douglas B Evans
Journal:  Arch Surg       Date:  2003-04

Review 4.  Medullary thyroid carcinoma.

Authors:  Y L Colson; S E Carty
Journal:  Am J Otolaryngol       Date:  1993 Mar-Apr       Impact factor: 1.808

Review 5.  RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.

Authors:  D J Marsh; L M Mulligan; C Eng
Journal:  Horm Res       Date:  1997

6.  A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.

Authors:  I Berndt; M Reuter; B Saller; K Frank-Raue; P Groth; M Grussendorf; F Raue; M M Ritter; W Höppner
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

7.  Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.

Authors:  L M Mulligan; D J Marsh; B G Robinson; I Schuffenecker; J Zedenius; C J Lips; R F Gagel; S I Takai; W W Noll; M Fink
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

8.  RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome?

Authors:  Oliver Gimm; Barbara E Niederle; Theresa Weber; Maximilian Bockhorn; Jörg Ukkat; Michael Brauckhoff; Phuong Nguyen Thanh; Andreja Frilling; Ernst Klar; Bruno Niederle; Henning Dralle
Journal:  Surgery       Date:  2002-12       Impact factor: 3.982

9.  Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A.

Authors:  S A Wells; D D Chi; K Toshima; L P Dehner; C M Coffin; S B Dowton; J L Ivanovich; M K DeBenedetti; W G Dilley; J F Moley
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

10.  Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene.

Authors:  L M Mulligan; C Eng; T Attié; S Lyonnet; D J Marsh; V J Hyland; B G Robinson; A Frilling; C Verellen-Dumoulin; A Safar
Journal:  Hum Mol Genet       Date:  1994-12       Impact factor: 6.150

View more
  8 in total

1.  Utilization of Genetic Testing for RET Mutations in Patients with Medullary Thyroid Carcinoma: a Single-Center Experience.

Authors:  Emily Parkhurst; Elise Calonico; Sridevi Abboy
Journal:  J Genet Couns       Date:  2018-06-27       Impact factor: 2.537

2.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

3.  RET gene mutations and polymorphisms in medullary thyroid carcinomas in Indian patients.

Authors:  B P Sharma; D Saranath
Journal:  J Biosci       Date:  2011-09       Impact factor: 1.826

4.  Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.

Authors:  Junyi Wang; Bin Zhang; Wensheng Liu; Yongxia Zhang; Xuebing Di; Yanmei Yang; Dangui Yan
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

5.  Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.

Authors:  Sara Milićević; Damijan Bergant; Tina Žagar; Barbara Perić
Journal:  Croat Med J       Date:  2021-04-30       Impact factor: 1.351

6.  Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994-2014: A Nationwide Study.

Authors:  Jes Sloth Mathiesen; Jens Peter Kroustrup; Peter Vestergaard; Kirstine Stochholm; Per Løgstrup Poulsen; Åse Krogh Rasmussen; Ulla Feldt-Rasmussen; Mette Gaustadnes; Torben Falck Ørntoft; Thomas van Overeem Hansen; Finn Cilius Nielsen; Kim Brixen; Christian Godballe; Anja Lisbeth Frederiksen
Journal:  Thyroid       Date:  2017-01-13       Impact factor: 6.568

7.  Medullary Thyroid Carcinoma and Associated Endocrinopathies in Slovenia from 1995 to 2021.

Authors:  Sara Milicevic; Mateja Krajc; Ana Blatnik; Barbara Peric
Journal:  Life (Basel)       Date:  2022-07-21

8.  Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study.

Authors:  Louise Vølund Larsen; Delphine Mirebeau-Prunier; Tsuneo Imai; Cristina Alvarez-Escola; Kornelia Hasse-Lazar; Simona Censi; Luciana A Castroneves; Akihiro Sakurai; Minoru Kihara; Kiyomi Horiuchi; Véronique Dorine Barbu; Francoise Borson-Chazot; Anne-Paule Gimenez-Roqueplo; Pascal Pigny; Stephane Pinson; Nelson Wohllk; Charis Eng; Berna Imge Aydogan; Dhananjaya Saranath; Sarka Dvorakova; Frederic Castinetti; Attila Patocs; Damijan Bergant; Thera P Links; Mariola Peczkowska; Ana O Hoff; Caterina Mian; Trisha Dwight; Barbara Jarzab; Hartmut P H Neumann; Mercedes Robledo; Shinya Uchino; Anne Barlier; Christian Godballe; Jes Sloth Mathiesen
Journal:  Endocr Connect       Date:  2020-06       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.